Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neural and Cognitive Changes with Solifenacin vs Mirabegron in OAB
NCT03817931Phase 4Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Aug 2019
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of solifenacin and mirabegron in overactive bladder (OAB) (3 arms), sponsored by Baylor Scott & White Research Institute. Primary endpoints: Functional connectivity on MRI at 30 days, Resting state blood oxygenation level dependent (BOLD) changes at 30 days and 1 more. Started Aug 2019; status: completed.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03817931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817931.